# Zevra Therapeutics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Zevra Therapeutics, Inc). ## Overview Zevra Therapeutics is a U.S.-based rare-disease pharmaceutical company focused on developing, commercializing, and expanding therapies for small patient populations with high unmet need. Its portfolio includes approved medicines, late-stage product candidates, and partnered assets spanning rare metabolic, neurologic, and genetic disorders. ## Products & services • MIPLYFFA for Niemann-Pick disease type C • OLPRUVA for urea cycle disorders • Celiprolol for vascular Ehlers-Danlos syndrome • KP1077IH for idiopathic hypersomnia • KP1077N for narcolepsy • AZSTARYS royalties and milestones • Global expanded access program support - **Commercial rare-disease therapies** (65%) — Approved medicines sold for rare disease indications, including MIPLYFFA and OLPRUVA. - **Partnered royalty income** (15%) — Royalties and milestone payments from partnered products such as AZSTARYS. - **Expanded access and reimbursement programs** (10%) — Revenue tied to global expanded access and related reimbursement arrangements. - **Clinical-stage pipeline assets** (10%) — Late-stage development programs including celiprolol and KP1077 candidates. - MIPLYFFA for Niemann-Pick disease type C - OLPRUVA for urea cycle disorders - Celiprolol for vascular Ehlers-Danlos syndrome - KP1077IH for idiopathic hypersomnia - KP1077N for narcolepsy - AZSTARYS royalties and milestones - Global expanded access program support ## Customers Zevra sells primarily to specialty pharmacies, distributors, and healthcare systems that dispense rare-disease medicines to patients under physician supervision. Its end users are patients with rare metabolic, neurologic, or genetic disorders, while physicians and treatment centers drive prescribing decisions and access pathways. The company also receives revenue from partners through royalties and milestones tied to licensed products. - **Specialty pharmacies** (primary) — Dispense approved rare-disease medicines such as MIPLYFFA to patients in the United States. - **International distributors** (primary) — Buy and distribute MIPLYFFA in the EU and select non-European territories. - **Physicians and treatment centers** (primary) — Prescribe and manage therapy for rare-disease patients, driving product adoption. - **Licensing partners** (secondary) — Generate royalty and milestone income from partnered assets such as AZSTARYS. - **Patients and caregivers** (secondary) — Use the therapies for chronic rare-disease treatment and access programs. - Specialty pharmacies dispensing MIPLYFFA in the U.S. - EU and ex-Europe distributors for MIPLYFFA access - Physicians treating rare metabolic and neurologic diseases - Patients with NPC, UCD, VEDS, hypersomnia, and narcolepsy - Partners paying royalties and milestones on licensed assets ## Geography The company is headquartered in the United States and commercializes MIPLYFFA there, while also pursuing broader access in Europe and select territories outside Europe through distributors and expanded access channels. OLPRUVA has rights in Geographical Europe through a licensing arrangement, and the company is pursuing European regulatory approval for MIPLYFFA. Geography matters because rare-disease commercialization depends on local regulatory approvals, reimbursement systems, and distribution partners. - **United States** (70%) — Core commercial market for MIPLYFFA and company headquarters - **Europe** (20%) — Regulatory expansion and licensed OLPRUVA territory - **Rest of world** (10%) — Select territories served through global expanded access - United States is the core commercial market for MIPLYFFA - Europe is a key expansion market for MIPLYFFA approval - OLPRUVA rights cover Geographical Europe through a license - Select non-European territories are served via global EAP - Local distributors are critical to product availability ## Strategy Zevra is focused on building a rare-disease franchise around commercial execution, late-stage development, and targeted business development. The company is prioritizing MIPLYFFA commercialization and geographic expansion, maintaining OLPRUVA, advancing celiprolol, and adding assets that fit its rare-disease infrastructure. - **Commercialize and expand MIPLYFFA** (short-term) — A marketed rare-disease product anchors the franchise and builds commercial infrastructure. - **Advance late-stage pipeline assets** (medium-term) — Late-stage programs can extend the company beyond a single commercial product. - **Add assets through business development** (medium-term) — Acquisitions and partnerships can broaden the portfolio without building everything internally. - **Focus R&D on higher-probability programs** (short-term) — Concentrating on late-stage and outsourced development improves capital efficiency. - Expand MIPLYFFA commercialization in the U.S. and abroad - Maintain and support OLPRUVA commercial availability - Advance celiprolol through late-stage development - Outsource early discovery to focus resources on later assets - Use business development to add rare-disease pipeline assets ## Risks Zevra depends on regulatory approvals, market acceptance, and third-party distribution to commercialize its rare-disease products. Its pipeline and international expansion also expose it to clinical, reimbursement, supply-chain, and foreign-operating risks that are common in specialty pharmaceuticals but amplified by small patient populations. - **Dependence on third-party distributors and specialty pharmacy channels** [high] — MIPLYFFA is distributed through a single specialty pharmacy in the U.S. and single distributors in other markets. - **Regulatory approval and compliance risk** [high] — Commercial growth depends on maintaining approvals and obtaining new ones in Europe and for pipeline assets. - **Market acceptance risk in rare diseases** [high] — Even approved therapies may not gain expected uptake if physicians, payors, or patients prefer alternatives. - **Clinical development risk** [high] — Late-stage candidates can fail to meet endpoints, delay launches, or require additional studies. - **Foreign operating and reimbursement risk** [medium] — International commercialization faces price controls, reimbursement differences, and currency volatility. - Single distributors can disrupt product availability - Regulatory approval risk for pipeline and ex-U.S. expansion - Small patient populations limit market adoption - Competition from better-funded pharma companies - Foreign reimbursement and currency risks affect expansion ## Accounting Revenue recognition depends on product sales, royalties, milestones, and expanded-access reimbursements, which can create timing differences across periods. Investors should also watch acquisition-related intangible assets and goodwill, because Zevra has grown through acquisitions and these balances are subject to impairment testing and valuation judgment. - **ASC 606 revenue recognition** — Can cause quarter-to-quarter volatility in reported revenue - **Goodwill impairment** — Non-cash impairment could materially affect earnings - **Definite-lived intangible assets** — Affects operating expense and potential impairment charges - **Milestone and royalty accounting** — Can create uneven revenue recognition - Product sales and royalties can shift revenue timing - Expanded access reimbursements may be episodic - Acquired intangibles require impairment testing - Goodwill is tested for impairment annually or on trigger - Milestones and license revenue depend on contract terms --- *Last updated: 2026-09-24T12:29:43.070282+00:00*